Subjects with preexisting cardiovascular symptoms who were receiving subutramine, an appetite suppressant, were found to be at increased risk of cardiovascular events while taking the drug. The study included 10162overweight or obese subjects with preexisting cardiovascular disease and/or type 2 diabetes. The subjects were randomly assigned to subutramine (5083subjects) or a placebo (5079 subjects) in a double‑blind fashion. The primary outcome measured was the occurrence of any of the following events: nonfatal myocardial infarction or stroke, resuscitation after cardiac arrest, or cardiovascular death. The primary outcome was observed in 572 subjects in the subutramine group and 506 subjects in the placebo group. Do the data give good reason to think that there is a difference between the proportions of treatment and placebo subjects who experienced the primary outcome? (Note that sibutramine has not been available in the United States since the end of 2010 due to its manufacturer's concerns over increased risk of heart attack or stroke, although at the present time, it can still be purchased in other countries.) State hypotheses and then find the test statistic. Give your answer to two decimal places. Use either software or the bottom row of Table C for the ?-value. Give your answer to four decimal places. State your conclusion. A conclusion cannot be made with the provided information. There is strong evidence that the proportion of subjects on sibutramine who are suffering a primary outcome differs from those who are on the placebo. There is no evidence that the proportion of subjects on sibutramine who are suffering a primary outcome differs from those who are on the placebo. There is very little evidence that the proportion of subjects on sibutramine who are suffering a primary outcome differs from those who are on the placebo.
Subjects with preexisting cardiovascular symptoms who were receiving subutramine, an appetite suppressant, were found to be at increased risk of cardiovascular
Do the data give good reason to think that there is a difference between the proportions of treatment and placebo subjects who experienced the primary outcome?
(Note that sibutramine has not been available in the United States since the end of 2010 due to its manufacturer's concerns over increased risk of heart attack or stroke, although at the present time, it can still be purchased in other countries.)
State hypotheses and then find the test statistic. Give your answer to two decimal places.
Use either software or the bottom row of Table C for the ?-value. Give your answer to four decimal places.
State your conclusion.
A conclusion cannot be made with the provided information.
There is strong evidence that the proportion of subjects on sibutramine who are suffering a primary outcome differs from those who are on the placebo.
There is no evidence that the proportion of subjects on sibutramine who are suffering a primary outcome differs from those who are on the placebo.
There is very little evidence that the proportion of subjects on sibutramine who are suffering a primary outcome differs from those who are on the placebo.
Trending now
This is a popular solution!
Step by step
Solved in 2 steps with 1 images
